ARCUTIS BIOTHERAPEUTICS, INC. Share-based Payment Arrangement, Expense
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Share-based Payment Arrangement, Expense of $12.76 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $12.76M, a 21.67% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $10.69M, a 9.33% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $10.06M, a 7.10% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $10.04M, a 2.01% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2025 was $40.36M, a 3.27% decline from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2024 was $41.73M, a 7.52% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2023 was $38.81M, a 18.76% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2022 was $32.68M, a 36.79% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.76M 10-Q · filed 2026-08-05 | $23.45M 10-Q · filed 2026-08-05 | $33.51M derived: sum of 3 quarters · filed 2026-08-05 | $43.55M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $10.69M 10-Q · filed 2026-05-06 | $20.75M derived: sum of 2 quarters · filed 2026-05-06 | $30.79M derived: sum of 3 quarters · filed 2026-05-06 | $41.27M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $10.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $20.09M derived: sum of 2 quarters · filed 2026-02-25 | $30.58M derived: sum of 3 quarters · filed 2026-08-05 | $40.36M 10-K · filed 2026-02-25 |
| 2025-09-30 | $10.04M 10-Q · filed 2025-10-28 | $20.52M derived: sum of 2 quarters · filed 2026-08-05 | $30.30M 10-Q · filed 2025-10-28 | $39.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $10.49M 10-Q · filed 2026-08-05 | $20.27M 10-Q · filed 2026-08-05 | $29.66M derived: sum of 3 quarters · filed 2026-08-05 | $39.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $9.78M 10-Q · filed 2026-05-06 | $19.17M derived: sum of 2 quarters · filed 2026-05-06 | $29.41M derived: sum of 3 quarters · filed 2026-05-06 | $41.94M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $9.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $19.63M derived: sum of 2 quarters · filed 2026-02-25 | $32.16M derived: sum of 3 quarters · filed 2026-02-25 | $41.73M 10-K · filed 2026-02-25 |
| 2024-09-30 | $10.24M 10-Q · filed 2025-10-28 | $22.76M derived: sum of 2 quarters · filed 2025-10-28 | $32.34M 10-Q · filed 2025-10-28 | $41.55M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $12.52M 10-Q · filed 2025-08-06 | $22.55M 10-Q · filed 2025-08-06 | $31.31M derived: sum of 3 quarters · filed 2026-02-25 | $41.31M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $10.03M 10-Q · filed 2025-05-06 | $18.79M derived: sum of 2 quarters · filed 2026-02-25 | $28.79M derived: sum of 3 quarters · filed 2026-02-25 | $39.36M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $8.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $18.76M derived: sum of 2 quarters · filed 2026-02-25 | $29.33M derived: sum of 3 quarters · filed 2026-02-25 | $38.81M 10-K · filed 2026-02-25 |
| 2023-09-30 | $10.00M 10-Q · filed 2024-11-06 | $20.58M derived: sum of 2 quarters · filed 2024-11-06 | $30.06M 10-Q · filed 2024-11-06 | $39.32M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $10.58M 10-Q · filed 2024-08-14 | $20.06M 10-Q · filed 2024-08-14 | $29.32M derived: sum of 3 quarters · filed 2025-02-25 | $38.11M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $9.48M 10-Q · filed 2024-05-14 | $18.74M derived: sum of 2 quarters · filed 2025-02-25 | $27.53M derived: sum of 3 quarters · filed 2025-02-25 | $35.63M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $9.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $18.05M derived: sum of 2 quarters · filed 2025-02-25 | $26.15M derived: sum of 3 quarters · filed 2025-02-25 | $32.68M 10-K · filed 2025-02-25 |
| 2022-09-30 | $8.79M 10-Q · filed 2023-11-03 | $16.89M derived: sum of 2 quarters · filed 2023-11-03 | $23.42M 10-Q · filed 2023-11-03 | $29.10M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $8.10M 10-Q · filed 2023-08-08 | $14.63M 10-Q · filed 2023-08-08 | $20.32M derived: sum of 3 quarters · filed 2024-02-27 | $25.68M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $6.53M 10-Q · filed 2023-05-09 | $12.22M derived: sum of 2 quarters · filed 2024-02-27 | $17.58M derived: sum of 3 quarters · filed 2024-02-27 | $21.92M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $5.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $11.05M derived: sum of 2 quarters · filed 2024-02-27 | $15.39M derived: sum of 3 quarters · filed 2024-02-27 | $23.89M 10-K · filed 2024-02-27 |
| 2021-09-30 | $5.36M 10-Q · filed 2022-11-08 | $9.70M derived: sum of 2 quarters · filed 2022-11-08 | $18.21M 10-Q · filed 2022-11-08 | $20.85M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $4.34M 10-Q · filed 2022-08-04 | $12.84M 10-Q · filed 2022-08-04 | $15.49M derived: sum of 3 quarters · filed 2023-02-28 | $17.75M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $8.50M 10-Q · filed 2022-05-05 | $11.15M derived: sum of 2 quarters · filed 2023-02-28 | $13.41M derived: sum of 3 quarters · filed 2023-02-28 | $15.46M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $2.64M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $4.90M derived: sum of 2 quarters · filed 2023-02-28 | $6.95M derived: sum of 3 quarters · filed 2023-02-28 | $7.94M 10-K · filed 2023-02-28 |
| 2020-09-30 | $2.26M 10-Q · filed 2021-11-04 | $4.31M derived: sum of 2 quarters · filed 2021-11-04 | $5.30M 10-Q · filed 2021-11-04 | $5.75M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $2.05M 10-Q · filed 2021-08-05 | $3.04M 10-Q · filed 2021-08-05 | $3.49M derived: sum of 3 quarters · filed 2022-02-22 | $3.63M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $990.00K 10-Q · filed 2021-05-06 | $1.45M derived: sum of 2 quarters · filed 2022-02-22 | $1.58M derived: sum of 3 quarters · filed 2022-02-22 | $1.72M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $455.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $594.00K derived: sum of 2 quarters · filed 2022-02-22 | $733.00K derived: sum of 3 quarters · filed 2022-02-22 | $824.00K 10-K · filed 2022-02-22 |
| 2019-09-30 | $139.00K 10-Q · filed 2020-11-05 | $278.00K derived: sum of 2 quarters · filed 2020-11-05 | $369.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $139.00K 10-Q · filed 2020-08-11 | $215.00K 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $76.00K 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $151.00K 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |